The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...